8-K: Synergy CHC Corp. Settles $12.7 Million Debt with Knight Therapeutics Through Cash and Equity Conversion

Synergy CHC Corp. announced it has satisfied $12.7 million in debt owed to Knight Therapeutics International S.A. through a combination of cash, an early payment discount, and the issuance of a pre-funded common stock purchase warrant.

Summary

• Synergy CHC Corp. (the "Company") satisfied $12,713,858 of debt previously owed to Knight Therapeutics International S.A. ("Knight").
• The debt satisfaction was achieved through a $10,000,000 cash repayment, an early payment discount of $1,213,858, and a conversion of $1,500,000 into equity.
• On June 11, 2025, the Company issued a pre-funded common stock purchase warrant (the "Pre-Funded Warrant") to Knight, allowing the purchase of up to 428,570 shares of common stock.
• The aggregate exercise price of the Pre-Funded Warrant, except for a nominal exercise price of $0.00001 per Warrant Share, was pre-funded to the Company.
• The Pre-Funded Warrant expires on the earlier of its full exercise or June 11, 2026, but can be automatically extended by one year if not fully exercised due to beneficial ownership limitations.
• The warrant may be exercised via a cashless exercise and will be automatically exercised via cashless exercise upon the earlier of June 11, 2026, or the closing of the next sale of equity securities of the Company.
• The Company relied on the exemption from registration provided by Section 4(a)(2) of the Securities Act for the issuance of the Pre-Funded Warrant.
• The Holder's exercise is subject to a Beneficial Ownership Limitation of 19.9% of the Company's outstanding common stock immediately after giving effect to the issuance of shares upon exercise.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant reduction in debt and the financial benefit from the early payment discount. However, the equity conversion and potential future dilution from the warrant introduce a slightly negative aspect, balancing the overall sentiment.

Positives

• The Company successfully satisfied $12,713,858 in debt, significantly reducing its liabilities.
• A substantial portion of the debt ($1,213,858) was eliminated through an early payment discount, representing a direct cost saving.
• The Pre-Funded Warrant means the Company has already received the primary consideration for the shares, eliminating future cash outlays upon exercise (except for a nominal $0.00001 per share).

Negatives

• The conversion of $1,500,000 of debt into equity and the issuance of the Pre-Funded Warrant will result in dilution for existing shareholders.
• The potential issuance of up to 428,570 new shares upon warrant exercise could further dilute ownership and earnings per share.

Risks

• Future equity dilution: The exercise of the Pre-Funded Warrant will increase the number of outstanding common shares, potentially diluting the value of existing shares.
• Market perception: The issuance of new equity or warrants, even for debt settlement, can sometimes be perceived negatively by the market due to potential future selling pressure.
• Beneficial Ownership Limitation: The 19.9% limitation on Knight's beneficial ownership could affect the timing and extent of warrant exercise, potentially prolonging the period of uncertainty regarding future share issuance.

Future Outlook

The Pre-Funded Warrant will be automatically exercised via cashless exercise upon the earlier of June 11, 2026, or the closing of the next sale of equity securities of the Company. This indicates a potential future increase in outstanding shares and possibly further equity financing activities.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 12, 2025 SYNERGY CHC CORP. By: /s/ Jack Ross Name: Jack Ross Title: Chief Executive Officer"

Industry Context

This announcement primarily concerns a specific corporate finance event – debt restructuring and equity issuance – rather than broader industry trends. It reflects the company's strategy to manage its balance sheet and debt obligations, which is a common practice across various industries, particularly for companies seeking to optimize their capital structure or reduce interest burdens.

Comparison to Industry Standards

• This transaction is a specific debt restructuring event for Synergy CHC Corp. and is not directly comparable to typical industry performance metrics or global benchmarks for operational results.
• Debt-to-equity conversions and warrant issuances are common mechanisms for companies to manage debt, especially with significant creditors, but the specific terms (e.g., pre-funded nature, 19.9% beneficial ownership limit) are tailored to this particular agreement with Knight Therapeutics International S.A.

Corporate Governance

Related Party Transactions

• The transaction involves the satisfaction of debt owed to Knight Therapeutics International S.A., a significant creditor of the Company, through a combination of cash, discount, and equity conversion.

Stakeholder Impact

• Shareholders: Potential dilution of existing shareholdings due to the conversion of debt into equity and the future exercise of the Pre-Funded Warrant.
• Creditors (Knight Therapeutics International S.A.): Their debt has been satisfied, partially through cash and partially by becoming a significant warrant holder, aligning their interests more closely with equity performance.

Next Steps

• Automatic cashless exercise of the Pre-Funded Warrant upon the earlier of June 11, 2026, or the closing of the next sale of equity securities of the Company.
• Potential future equity sales by the Company, which would trigger the automatic exercise of the warrant.

Key Dates

Keywords

Synergy CHC Corp, SNYR, SEC filing, 8-K, debt settlement, equity conversion, pre-funded warrant, common stock, Knight Therapeutics International S.A., unregistered sales of equity securities, corporate finance, dilution, warrant